Carla Pereira Gomes

Carla Pereira Gomes

Auto-generated profile, based on publicly available information

Carla Pereira Gomes

Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2017 in Biomaterials
Verified
Journal Article
Open access
CLCátia D.F. Lopes
Cátia D.F. Lopes
NGNádia Gonçalves
Nádia Gonçalves
CGCarla P. Gomes
Carla P. Gomes
MSMaria Joao Saraiva
Maria Joao Saraiva
APAna Paula Pêgo
Ana Paula Pêgo
Neuron-targeted gene delivery is a promising strategy to treat peripheral neuropathies. Here we propose the use of polymeric nanoparticles based on thiolated trimethyl chitosan (TMCSH) to mediate targeted gene delivery to peripheral neurons upon a peripheral and minimally invasive intramuscular administration. Nanoparticles were grafted with the non-toxic carboxylic fragment of the tetanus neurotoxin (HC) to allow neuron targeting and were explored to deliver a plasmid DNA encoding for the brain-derived neurotrophic factor (BDNF) in a peripheral nerve injury model. The TMCSH-HC/BDNF nanoparticle treatment promoted the release and significant expression of BDNF in neural tissues, which resulted in an enhanced functional recovery after injury as compared to control treatments (vehicle and non-targeted nanoparticles), associated with an improvement in key pro-regenerative events, namely, the increased expression of neurofilament and growth-associated protein GAP-43 in the injured nerves. Moreover, the targeted nanoparticle treatment was correlated with a significantly higher density of myelinated axons in the distal stump of injured nerves, as well as with preservation of unmyelinated axon density as compared with controls and a protective role in injury-denervated muscles, preventing them from denervation. These results highlight the potential of TMCSH-HC nanoparticles as non-viral gene carriers to deliver therapeutic genes into the peripheral neurons and thus, pave the way for their use as an effective therapeutic intervention for peripheral neuropathies.

5 August 2019 in BMC Cancer
Verified
Journal Article
Open access
PDF file
CGCarla Pereira Gomes
Carla Pereira Gomes
SNSandrina Nóbrega-Pereira
Sandrina Nóbrega-Pereira
BDBeatriz Domingues-Silva
Beatriz Domingues-Silva
KRKenny Rebelo
Kenny Rebelo
CACatarina Alves-Vale
Catarina Alves-Vale
BJBruno Bernardes de Jesus
Bruno Bernardes de Jesus
Long non-coding RNAs (lncRNAs) represent a substantial portion of the human transcriptome. LncRNAs present a very stringent cell-type/tissue specificity being potential candidates for therapeutical applications during aging and disease. As example, targeting of MALAT1, a highly conserved lncRNA originally identified in metastatic non-small cell lung cancer, has shown promising results in cancer regression. Nevertheless, the regulation and specificity of MALAT1 have not been directly addressed. Interestingly, MALAT1 locus is spanned by an antisense transcript named TALAM1. Here using a collection of breast cancer cells and in vitro and in vivo migration assays we characterized the dynamics of expression and demonstrated that TALAM1 regulates and synergizes with MALAT1 during tumorigenesis. Down-regulation of TALAM1 was shown to greatly impact on the capacity of breast cancer cells to migrate in vitro or to populate the lungs of immunocompromised mice. Additionally, we demonstrated that TALAM1 cooperates with MALAT1 in the regulation of the properties guiding breast cancer aggressiveness and malignancy. By characterizing this sense/anti-sense pair we uncovered the complexity of MALAT1 locus regulation, describing new potential candidates for cancer targeting.

1 September 2018 in Acta Biomaterialia
Verified
Journal Article
Closed access
CGCarla Pereira Gomes
Carla Pereira Gomes
VLVictoria Leiro
Victoria Leiro
CLCátia Daniela Ferreira Lopes
Cátia Daniela Ferreira Lopes
ASAna Spencer
Ana Spencer
APAna Paula Pêgo
Ana Paula Pêgo

12 June 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ASAna Sadio
Ana Sadio
JGJenny K Gustafsson
Jenny K Gustafsson
BPBruno Pereira
Bruno Pereira
CGCarla Pereira Gomes
Carla Pereira Gomes
GHGunnar C Hansson
Gunnar C Hansson
RARaquel Almeida
Raquel Almeida
Development of effective non-viral vectors is of crucial importance in the implementation of RNA interference in clinical routine. The localized delivery of siRNAs to the gastrointestinal mucosa is highly desired but faces specific problems such as the stability in gastric acidity conditions and the presence of the mucus barrier. CDX2 is a transcription factor critical for intestinal differentiation being involved in the initiation and maintenance of gastrointestinal diseases. Specifically, it is the trigger of gastric intestinal metaplasia which is a precursor lesion of gastric cancer. Its expression is also altered in colorectal cancer, where it may constitute a lineage-survival oncogene. Our main objective was to develop a nanoparticle-delivery system of siRNA targeting CDX2 using modified chitosan as a vector. CDX2 expression was assessed in gastric carcinoma cell lines and nanoparticles behaviour in gastrointestinal mucus was tested in mouse explants. We show that imidazole-modified chitosan and trimethylchitosan/siRNA nanoparticles are able to downregulate CDX2 expression and overpass the gastric mucus layer but not colonic mucus. This system might constitute a potential therapeutic approach to treat CDX2-dependent gastric lesions.

10 January 2014 in MRS Bulletin
Verified
Journal Article
Open access
PDF file
CGCarla Pereira Gomes
Carla Pereira Gomes
CLCátia Daniela Ferreira Lopes
Cátia Daniela Ferreira Lopes
PMPedro Miguel Duarte Moreno
Pedro Miguel Duarte Moreno
AVAida Varela-Moreira
Aida Varela-Moreira
MAMaria Jose Alonso
Maria Jose Alonso
APAna Paula Pêgo
Ana Paula Pêgo
Translating chitosan to clinical delivery of nucleic acid-based drugs - Volume 39 Issue 1 - Carla Pereira Gomes, Cátia Daniela Ferreira Lopes, Pedro Miguel Duarte Moreno, Aida Varela-Moreira, Maria José Alonso, Ana Paula Pêgo

11 January 2016 in Molecular Pharmaceutics
Verified
Journal Article
Open access
PMPedro M. D. Moreno
Pedro M. D. Moreno
JSJoyce C. Santos
Joyce C. Santos
CGCarla P. Gomes
Carla P. Gomes
AVAida Varela-Moreira
Aida Varela-Moreira
ACArtur Costa
Artur Costa
APAna Paula Pêgo
Ana Paula Pêgo
Splice switching oligonucleotides (SSOs) are a class of single-stranded antisense oligonucleotides (ssONs) being used as gene therapeutics and demonstrating great therapeutic potential. The availability of biodegradable and biocompatible delivery vectors that could improve delivery efficiencies, reduce dosage, and, in parallel, reduce toxicity concerns could be advantageous for clinical translation. In this work we explored the use of quaternized amphiphilic chitosan-based vectors in nanocomplex formation and delivery of splice switching oligonucleotides (SSO) into cells, while providing insights regarding cellular uptake of such complexes. Results show that the chitosan amphiphilic character is important when dealing with SSOs, greatly improving colloidal stability under serum conditions, as analyzed by dynamic light scattering, and enhancing cellular association. Nanocomplexes were found to follow an endolysosomal route with a long lysosome residence time. Conjugation of a hydrophobic moiety, stearic acid, to quaternized chitosan was a necessary condition to achieve transfection, as an unmodified quaternary chitosan was completely ineffective. We thus demonstrate that amphiphilic quaternized chitosan is a biomaterial that holds promise and warrants further development as a platform for SSO delivery strategies.